(IVVD) Invivyd, Inc. Business Model Canvas Research

Invivyd, Inc. relies on CDMO manufacturing partners to make antibody drug substance and finished product, so it can keep GMP control without building a costly plant. That setup supports scale-up and supply continuity, and in 2025 Invivyd still ran an outsourced model focused on preserving cash for R&D and commercialization.

• Outsourced GMP manufacturing
• Supports scale-up
• Helps supply continuity
• Reduces plant capital needs

Healthcare distribution partners are critical for Invivyd, Inc.’s IV monoclonal antibody model because hospitals, infusion centers, and specialty distributors handle storage, cold-chain logistics, and site access. For IV biologics, the delivery step is part of the product value chain, so these partners directly affect how fast patients can receive treatment and how reliably inventory moves.

• Hospitals and infusion centers reach patients.
• Specialty distributors manage cold-chain flow.
• Partners expand site access and scheduling.

Invivyd’s GMP manufacturing centers on biologics production, testing, and batch release, and it is vital for keeping preventive antibody supply reliable. In 2025, that reliability directly affects launch timing and inventory coverage, since any delay in release can slow patient access and strain working capital.

• Biologics made under GMP rules
• Testing before batch release
• Supply uptime supports launches
• Inventory depends on release speed

Invivyd, Inc. turns science into sales by backing physician education, payer access, and adverse-event reporting around its authorized biologic. For an EUA product, post-market surveillance is mandatory, so safety monitoring is part of commercialization, not an add-on.

• Educate physicians on use
• Support payer coverage access
• Report adverse events fast
• Track safety after launch

This keeps the product in real-world use and helps convert regulatory authorization into revenue.

Invivyd, Inc. leans on variant and neutralization datasets to show how its antibodies perform against circulating strains, and that evidence guides lead-candidate picks and public health claims. In 2025, this kind of lab data stayed central as SARS-CoV-2 kept shifting, so the company used it to decide when a candidate still matched current variants and when updates were needed.

Invivyd uses CDMOs, CROs, and specialist vendors to expand manufacturing and trial capacity without owning heavy plants or a large fixed-cost base. This outsourced network is a core operating resource, letting Invivyd scale work fast while keeping capital tied up in R&D and clinical execution.

• CDMOs add manufacturing capacity.
• CROs support trial operations.
• Specialists reduce fixed assets.

Invivyd, Inc.'s clinic-administered dosing fits an IV monoclonal antibody model: pemivibart is given as a 450 mg infusion over about 60 minutes in a controlled setting, so staff can monitor reactions and manage higher-risk patients who need clinician oversight.

• Controlled infusion setting
• Real-time monitoring during dosing
• Best fit for high-risk patients

Invivyd, Inc. uses the same antibody-discovery engine across influenza and beta-coronavirus programs, so the platform is not tied to one virus family. That creates optionality for future infectious-disease assets and supports a broader pipeline beyond COVID-19, with the company reporting $128.9 million in cash, cash equivalents, and short-term investments as of Dec. 31, 2024.

• One discovery engine, two virus families
• Broader pipeline, lower single-virus risk
• Builds future infectious-disease optionality

Invivyd, Inc. uses medical information support to give healthcare professionals dosing, safety, and variant-activity updates, with medical affairs answering questions and sharing new evidence fast. In a viral market that can change in months, this keeps clinical use aligned with the latest data and label changes.

• Dosing guidance for HCPs
• Safety and evidence updates
• Variant activity changes fast

Invivyd, Inc. keeps customer relationships active after product use through pharmacovigilance follow-up, where safety events and real-world outcomes are tracked to meet reporting duties and support continued confidence. In 2025, this post-use monitoring remained tied to every treated patient, with 100% of reported adverse events feeding the companys safety review process.

• Tracks safety after use
• Records adverse events
• Supports compliance and trust

Clinical and academic sites give Invivyd, Inc. direct access to research centers that run trials, collect real-world evidence, and reach investigators. This channel also helps turn study outputs into publication-quality data, which supports both pipeline development and clinician adoption.

• Trial execution
• Real-world evidence
• Investigator outreach
• Publishable data

Invivyd uses three main channels—its website, investor presentations, and medical congress activity—to share access data, clinical updates, and corporate news. These channels help educate physicians and investors, while also keeping the market informed through SEC-linked materials and conference readouts.

• Website: data, access, updates
• Presentations: investor visibility
• Congresses: medical education

Specialist healthcare providers are the gatekeepers for Invivyd, Inc.: infectious disease, transplant, and immunology clinicians decide who is eligible, when to treat, and how to weigh risk. PEMGARDA received U.S. FDA emergency use authorization in 2024, so provider acceptance is the key practical market segment for this specialty biologic.

• Clinicians drive eligibility checks.
• Timing matters for high-risk patients.
• Adoption depends on provider trust.

Hospitals, integrated delivery networks, and insurers are the gatekeepers for Invivyd, Inc.'s use in care pathways, because they decide access, site of care, and reimbursement. They focus on outcomes, utilization, and total cost, so one approved protocol can drive scale fast, while weak coverage can stall adoption.

• Access depends on formulary and prior auth
• Value tied to fewer admissions and visits
• Coverage decisions shape revenue scale

Commercial SG&A covers the launch and support of Invivyd, Inc.’s specialty products: field sales, medical affairs, payer reimbursement, and admin. As commercialization scales, this line usually rises fast; in a launch phase, these costs can outweigh product revenue before volume builds.

• Sales and medical affairs drive launch spend
• Reimbursement support is payer-heavy
• Public-company G&A adds overhead
• Costs rise with commercialization scale

Invivyd, Inc. must keep up FDA filings, safety reports, and patent work, so regulatory, legal, and IP costs stay ongoing. In biopharma, exclusivity often depends on a 20-year patent term, and FDA authorization also requires continuous compliance after launch.

• Ongoing filings and safety reporting
• Legal spend protects exclusivity
• IP costs defend patent life

Invivyd can earn licensing and royalty income if it lets other companies use its antibodies or other IP, so the company gets paid from sales without funding full commercialization. That model is lighter on cash than building its own launch, and biopharma royalties often land in the low-single-digit to mid-single-digit range of net sales.

• Monetizes IP without full launch spend
• Royalty rates often low-single-digit
• Scales with partner sales, not Invivyd spend

Research grants can fund selected programs without issuing new shares, so they cut dilution for Invivyd, Inc. and fit early or public-health work. In 2025, this matters because R&D-heavy biotech still burns cash before steady product sales, and non-dilutive support can bridge that gap.

• Lower dilution for existing holders
• Best for early-stage science
• Useful for public-health programs